KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks
$5.03
+0.150 (+3.07%)
At Close: Apr 26, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $4.61 $7.24 Friday, 26th Apr 2024 AFMD stock ended at $5.03. This is 3.07% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 6.35% from a day low at $4.88 to a day high of $5.19.
90 days $4.25 $7.24
52 weeks $2.24 $11.10

Historical Affimed N.V. prices

Date Open High Low Close Volume
Mar 24, 2022 $43.90 $44.90 $43.65 $44.30 108 600
Mar 23, 2022 $42.40 $44.40 $41.70 $42.70 68 260
Mar 22, 2022 $41.60 $43.75 $41.05 $43.00 98 501
Mar 21, 2022 $42.10 $42.40 $40.65 $41.20 71 719
Mar 18, 2022 $44.50 $44.75 $42.50 $42.80 153 138
Mar 17, 2022 $43.30 $45.30 $43.20 $44.60 106 550
Mar 16, 2022 $43.90 $44.30 $42.65 $43.80 90 490
Mar 15, 2022 $42.10 $43.20 $41.50 $43.10 57 690
Mar 14, 2022 $44.80 $44.80 $41.50 $42.10 96 310
Mar 11, 2022 $45.60 $46.50 $44.65 $44.70 94 350
Mar 10, 2022 $44.60 $45.40 $43.95 $45.20 54 670
Mar 09, 2022 $42.80 $45.90 $42.80 $45.40 123 300
Mar 08, 2022 $40.90 $43.10 $40.35 $41.70 80 990
Mar 07, 2022 $41.00 $42.20 $40.70 $41.10 83 430
Mar 04, 2022 $41.60 $42.80 $40.60 $40.90 46 310
Mar 03, 2022 $44.80 $45.10 $42.00 $42.40 80 420
Mar 02, 2022 $44.00 $45.20 $43.60 $44.80 61 710
Mar 01, 2022 $44.20 $45.00 $43.35 $43.90 95 560
Feb 28, 2022 $45.10 $45.70 $43.90 $44.10 121 200
Feb 25, 2022 $44.70 $45.90 $43.65 $45.90 112 540
Feb 24, 2022 $40.30 $44.60 $40.00 $44.40 130 250
Feb 23, 2022 $44.60 $44.60 $41.92 $42.20 104 170
Feb 22, 2022 $41.30 $43.35 $41.30 $42.30 100 750
Feb 18, 2022 $43.20 $43.70 $41.75 $42.20 72 340
Feb 17, 2022 $44.30 $44.60 $42.90 $43.60 91 120
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Golden Star

Ticker Date Change Price
DHT Apr 24 2.04% $11.28
MLI Apr 19 9.66% $52.28
LPLA Apr 19 1.42% $262.59
DOOR Apr 18 0.167% $131.39
LNG Apr 17 1.49% $156.81
FCN Apr 16 1.80% $207.62
ELV Apr 16 5.97% $506.97
AKR Apr 05 4.78% $16.53
ITCI Apr 05 7.04% $68.44
VSTS Apr 04 0.425% $18.82
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT